Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

King Merger With Jones Will Support Altace Marketing To Diabetic Patients

  • News

Executive Summary

King Pharmaceuticals' merger with Jones Pharma will provide support for marketing of King's ACE inhibitor Altace to diabetic patients, the company indicated.

You may also be interested in...



Novavax To Increase Sales Force To 100; Will Co-Promote Estrasorb With King

Novavax plans to ramp up its sales force from 65 reps to 100 reps in preparation for the launch of its estrogen replacement cream Estrasorb.

Novavax To Increase Sales Force To 100; Will Co-Promote Estrasorb With King

Novavax plans to ramp up its sales force from 65 reps to 100 reps in preparation for the launch of its estrogen replacement cream Estrasorb.

Altace Will Gain 1,000 Wyeth Reps Through Copromotion Deal

Wyeth-Ayerst is allocating approximately 1,000 sales reps to promote King's Altace in the U.S. and Puerto Rico, under a copromotion agreement announced June 23.

Table

View full table

Tags:
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS036344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By